araag2/HINT huggingface dataset:
Clinical trial NCT00496392 (phase 3, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: nasal fentanyl
SMILES: CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult in- or out patient with cancer and breakthrough pain; using a stable, chronic
             opioid treatment for background pain.

          -  Minimum three BTP episodes per week and maximum four per day. Life expectancy of at
             least three months.

          -  Chemotherapy and palliative radiotherapy (except facial radiotherapy) are allowed.

          -  Randomisation in previous studies with NF, i.e. FT-016-IM, FT-017-IM or FT-018-IM, is
             not allowed.

          -  Previous use of Actiq is accepted.
Clinical trial NCT00302211 (phase 3, status: terminated)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: inhaled iloprost (5 μg), inhaled placebo, sildenafil, bosentan
SMILES: [H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O, CC1=CC(O)=CC(C)=C1Cl, CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1, COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Reason stopped: 
    terminated due to slow enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Aged 12-85 years; of either gender.

          -  Confirmed PAH due to idiopathic pulmonary arterial hypertension (IPAH) or familial
             pulmonary arterial hypertension (FPAH).

          -  6-minute walk distance (6-MWD) between 100-450 meters at screening.

          -  On a stable dose of sildenafil, with or without bosentan.

        Exclusion Criteria:

          -  Any treatment for PAH with prostacyclins, prostacyclin analogues, endothelin-1
             antagonists, or phosphodiesterase-5 (PDE-5) inhibitors other than sildenafil within
             the past 12 weeks.

          -  Pulmonary hypertension due to conditions other than those stated in inclusion
             criteria.

          -  Additional PAH medications added within the past 12 weeks.
Clinical trial NCT00451451 (phase 3, status: completed)
Conditions: relapsing-remitting multiple sclerosis
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: bg00012, placebo, glatiramer acetate
SMILES: [H]\C(=C(\[H])C(=O)OC)C(=O)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(O)=O
Eligibility criteria:

        Unless otherwise specified, to be eligible to participate in this study, candidates must
        meet the following eligibility criteria at the time of the randomization:

        Key Inclusion Criteria:

          -  Must have confirmed diagnosis of RRMS according to McDonald criteria #1-4

          -  Must have a baseline EDSS between 0.0 and 5.0, inclusive.

          -  Must have relapsing-remitting disease course.

        Key Exclusion Criteria:

          -  Other chronic disease of immune system, malignancies, urologic, pulmonary,
             gastrointestinal disease

          -  Pregnant or nursing women

        Note: Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01452698 (phase 3, status: completed)
Conditions: erosive esophagitis
ICD codes: B37.81, K20.0, K20.80, K20.81, K20.90, K20.91, K21.9
Drugs: tak-438, placebo, lansoprazole, placebo
SMILES: CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. At Visit 1 (start of the observation period), the participant must have endoscopically
             confirmed erosive esophagitis of Grade A to D, as defined by the LA classification
             grading system, and the target number of participants who are clearly Grade C or D is
             30% (120 participants) or more of the total participants.

          2. Outpatient (including inpatient for examination)

        Exclusion Criteria:

          1. Participants with an esophagus-related complication (eosinophilic esophagitis,
             esophageal varices, scleroderma, viral or fungal infection, esophageal stenosis,
             etc.), a history of radiotherapy or cryotherapy of the esophagus, a caustic or
             physiochemical trauma (esophageal sclerotherapy, etc.). However, participants with
             Schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) or
             Barrett's esophagus are allowed to be included.

          2. Participants who have received surgery or treatment affecting gastroesophageal reflux
             (cardioplasty, dilation of esophageal stenosis [excluding Schatzki's ring], etc.), or
             who have a history of surgery of stomach or duodenum (excluding removal of benign
             polyp under endoscopy)

          3. Participants who have acute upper gastrointestinal bleeding, gastric or duodenal ulcer
             (mucosal defect with white coating) within 30 days prior to Visit 1 (start of the
             observation period). However, participants with gastric or duodenal erosions are
             allowed to be included.

          4. Participants with a previous or current history of Zollinger-Ellison syndrome, or
             other gastric acid hypersecretion disorders
Clinical trial NCT00407030 (phase 3, status: completed)
Conditions: cervical dystonia
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90
Drugs: incobotulinumtoxina (xeomin) (240 units), incobotulinumtoxina (xeomin) (120 units), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  Male or female outpatients between ages 18 and 75 years inclusive)

          -  A clinical diagnosis of cervical dystonia (i.e. spasmodic torticollis) with
             predominantly rotational form and a need for injection (determined by the Toronto
             Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total score)

          -  TWSTRS-Total score >= 20

          -  TWSTRS-Severity score >= 10

          -  TWSTRS-Disability score >= 3

          -  TWSTRS-Pain score >= 1

          -  On a stable dose of medications (if any) used for focal dystonia treatment (e.g.
             anticholinergics and benzodiazepines) for at least 3 months prior to and expected
             throughout the Main Period

          -  For pre-treated patients only: Source documentation of the last two consecutive
             injection sessions with Botulinum Toxin and stable therapeutic response directly prior
             to trial entry

          -  For pre-treated patients only: At least 10 weeks must have been passed between the
             last injection with Botulinum Toxin for cervical dystonia and baseline

          -  For pre-treated patients only: The most recent injection with Botulinum Toxin must
             have been maximal 300 Units of type A or 12,000 Units of type B

        Main Exclusion Criteria:

          -  Traumatic torticollis or tardive torticollis

          -  TWSTRS-Severity score for anterocollis >= 2 points (pure anterocollis)

          -  TWSTRS-Severity score for retrocollis >= 2 points (pure retrocollis)

          -  Myotomy or denervation surgery in the affected muscles (e.g. peripheral denervation
             and/or spinal cord stimulation)

          -  Hypersensitivity to human serum albumin, sucrose, or Botulinum Toxin Type A

          -  Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis,
             or any other significant neuromuscular disease which might interfere with the trial

          -  Current swallowing disorder of any origin (dysphagia scale >= 3, i.e. severe, with
             swallowing difficulties and requiring a change in diet)

          -  Marked limitation on passive range of motion that suggests contractures or other
             structural abnormality, e.g. cervical contractures or cervical spine syndrome

          -  Treatment with Botulinum Toxins for any indication other than cervical dystonia within
             4 months prior to baseline and during the trial
Clinical trial NCT00389779 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: darusentan, guanfacine, darusentan placebo
SMILES: COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C2=CC=CC=C2)C2=CC=CC=C2)=N1, NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl, COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C2=CC=CC=C2)C2=CC=CC=C2)=N1
Eligibility criteria:

        SELECTED INCLUSION CRITERIA:

          1. Subjects who are competent to provide written consent;

          2. Aged 35 to 80 years;

          3. Subjects with diabetes and/or chronic kidney disease must have an average sitting
             systolic blood pressure greater than or equal to 130 mmHg;

          4. All other subjects must have an average sitting systolic blood pressure greater than
             or equal to 140 mmHg;

          5. Receiving and adhering to full doses of appropriate guideline-recommended
             antihypertensive drugs from three different classes of antihypertensive agents,
             including a diuretic;

          6. Female subjects of non-childbearing potential (i.e., post-menopausal for at least 2
             years or surgically sterile).

        SELECTED EXCLUSION CRITERIA:

          1. Average sitting systolic and diastolic blood pressure greater than or equal to 180
             mmHg and 110 mmHg, respectively;

          2. Subjects treated with a central alpha-2 agonist and/or imidazoline receptor agonist;

          3. Left ventricular dysfunction;

          4. Serum ALT or AST greater than 2 times the Upper Limit of Normal;

          5. Subjects who have experienced myocardial infarction, unstable angina pectoris, or a
             cerebrovascular accident within 6 months; or sick sinus syndrome or second or third
             degree atrioventricular block, atrial fibrillation or recurrent atrial tachycardia,
             recurrent ventricular tachycardia, or symptomatic bradycardia;

          6. Implanted pacemakers or cardioverter defibrillator;

          7. Symptomatic congestive heart failure requiring treatment;

          8. Hemodynamically significant valvular heart disease;

          9. Hemodialysis or peritoneal dialysis, or history of renal transplant;

         10. Type I diabetes mellitus;

         11. Diagnosis or recurrence of malignancy within the past 3 years;

         12. Sleep apnea, unless a recent sleep study demonstrated arterial oxygenation saturation
             greater than or equal to 90%, treated or untreated;

         13. Subjects who perform alternating shift or night work;

         14. Subjects who have participated in a clinical study involving another investigational
             drug or device within 4 weeks prior to Screening
Clinical trial NCT00223613 (phase 3, status: unknown status)
Conditions: type 1 diabetes
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: daily intranasal administration of insulin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  children carrying HLA-conferred genetic risk for developing type 1 diabetes

          -  have had at least two types of autoantibodies of ICA, IAA, GADA and IA-2A in at least
             two consecutive blood samples drawn at least 3 months apart

          -  age at least one year

        Exclusion Criteria:

          -  severe other disease

          -  age above 15 years
Clinical trial NCT01850602 (phase 3, status: completed)
Conditions: hemodialysis, hyperphosphatemia
ICD codes: I95.3, R88.0, Z49.31
Drugs: pa21, sevelamer hydrochloride
SMILES: O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O, NCC=C.ClCC1CO1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients age 20 or older, regardless of gender.

          -  Receiving stable maintenance hemodialysis 3 times a week.

          -  Patients not having changed their phosphate binder agent dose, for 4 weeks or more
             before their observation period start.

        Exclusion Criteria:

          -  Patients having history of a pronounced brain / cardiovascular disorder.

          -  Patients having severe gastrointestinal disorders.

          -  Patients having severe hepatic disorders.
Clinical trial NCT00633893 (phase 3, status: completed)
Conditions: venous thrombosis
ICD codes: K64.5, I67.6, O87.3, O22.50, O22.51, O22.52, O22.53
Drugs: apixaban, placebo
SMILES: COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women ≥ 18 years of age;

          -  Clinical diagnosis of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE);

          -  Anticoagulant treatment completed

          -  No recurrence of Venous Thromboembolism (VTE)

        Exclusion Criteria:

          -  Subjects with indications for long-term treatment with a vitamin K antagonist

          -  Active bleeding or high risk for serious bleeding

          -  Short life expectancy

          -  Uncontrolled high blood pressure

          -  Impaired kidney or liver function
Clinical trial NCT00442026 (phase 3, status: terminated)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: docetaxel, gemcitabine, gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    due to poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically- or cytologically- confirmed Non-Small-Cell Lung Cancer

          -  Stage IIIB/IV

          -  No prior chemotherapy

          -  Presence of two-dimensional measurable disease. The measurable disease should not have
             been irradiated.

          -  Absence or irradiated and stable central nervous system metastatic disease

          -  Life expectancy of more than 3 months

          -  Age ≥ 70 years.

          -  Performance status (WHO) < 3

          -  Patients "non-frail" according to comprehensive geriatric assessment

          -  Adequate bone marrow function (Absolute neutrophil count > 1000/mm^3, Platelet count >
             100000/mm^3, Hemoglobin > 9gr/mm^3).

          -  Adequate liver (Bilirubin < 1.5 times upper limit of normal and SGOT/SGPT < 2 times
             upper limit of normal) and renal function (creatinine < 2mg/dl).

          -  Adequate cardiac function (LVEF > 50%).

          -  Informed consent.

        Exclusion Criteria:

          -  Psychiatric illness or social situation that would preclude study compliance.

          -  Other concurrent uncontrolled illness.

          -  Other invasive malignancy within the past 5 years except nonmelanoma skin cancer.

          -  No presence of a reliable care giver

          -  Other concurrent investigational agents.
Clinical trial NCT01028079 (phase 3, status: completed)
Conditions: low back pain
ICD codes: M54.50, M54.51, M54.59
Drugs: acetylsalicylic acid (aspirin, baye4465), ibuprofen, placebo
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O, CC1=CC(O)=CC(C)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ambulatory male or female, 18 to 70 years of age

          -  Body mass index ranging in-between 18 and 30 kg/m²

          -  Normal blood pressure

          -  Patients suffering from low back pain

          -  Low back pain, localized below the costal margin and above the inferior gluteal folds,
             either as acute low back pain, or as chronic or intermittent low back pain

        Exclusion Criteria:

          -  Hypersensitivity to acetylsalicylic, salicylates, or other Non Steroidal
             Anti-inflammatory drugs

          -  Serious physical illness especially uncontrolled disorders of kidney, liver, lung,
             heart or brain function, neurological disorders or severe chronic or terminal disease

          -  Pregnancy or lactation period

          -  Abuse of alcohol or addictive substances
Clinical trial NCT00500318 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: aclidinium bromide, placebo
SMILES: OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of stable moderate to severe COPD (GOLD 2006); post-levalbuterol FEV1
             >=30% and < 80% predicted and FEV1/FVC<70% predicted

          -  Current or former cigarette smoker

          -  Functional Residual Capacity (FRC) measured by body plethysmography >= 120% of
             predicted value

          -  Baseline Dyspnea Index (BDI) focal score ≤ 7 at Visit 4

        Exclusion Criteria:

          -  History of presence of asthma, allergic rhinitis, or atopy

          -  Hospitalization for acute COPD exacerbation in the 3 months prior to study entry

          -  Respiratory tract infection (including the upper respiratory tract) or COPD
             exacerbation in the 6 weeks prior to study entry

          -  Clinically significant respiratory conditions other than COPD

          -  Chronic use of oxygen therapy >= 15 hours a day
Clinical trial NCT01306461 (phase 3, status: completed)
Conditions: ocular hypertension, open-angle glaucoma
ICD codes: H40.053, H40.051, H40.052, H40.059, H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131
Drugs: timolol and tafluprost, fixed dose combination of tafluprost and timolol
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1, [H][C@](O)(CNC(C)(C)C)COC1=NSN=C1N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Aged 18 years or more

          -  A diagnosis of ocular hypertension or open-angle glaucoma

          -  Meet specific IOP level at visit 1 (screening)and visit 2 (baseline)

          -  Meet specific visual acuity score

          -  Are willing to follow instructions

          -  Have provided a written informed consent

        Exclusion Criteria:

          -  Females who are pregnant, nursing or planning pregnancy

          -  IOP greater than 36 mmHg at any time point at screening or baseline

          -  Diagnosis of angle-closure glaucoma or secondary glaucoma other than capsular or
             pigmentary glaucoma in either eye

          -  Suspected contraindication or hypersensitivity to study medications tafluprost or
             timolol (e.g. asthma, low pulse) or to wash-out medication brinzolamide

          -  Glaucoma filtration surgery or any other ocular surgery (including ocular laser
             procedures) within 6 months prior to Screening

          -  Use of contact lenses at Screening or during the study

          -  Presence of any abnormality or significant illness that could be expected to interfere
             with the patient safety or study parameters

          -  Current participation in another clinical trial within the last 30 days
Clinical trial NCT00315237 (phase 3, status: completed)
Conditions: transitional cell carcinoma of the urothelial tract, bladder cancer, bladder neoplasms
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4, D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: vinflunine and best supportive care
SMILES: CC[C@@]12C=CCN3CC[C@@]4([C@H]13)[C@@H](N(C)C1=CC(OC)=C(C=C41)[C@]1(C[C@@H]3C[C@H](C[N@@](C3)CC3=C1NC1=CC=CC=C31)C(C)(F)F)C(=O)OC)[C@](O)([C@@H]2OC(C)=O)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Bladder cancer

          -  Progressed after 1st line platinum-chemotherapy

          -  >= 18 years old

          -  Adequate hematologic, hepatic & renal function

        Exclusion Criteria:

          -  CNS disease

          -  Moderate neuropathy

          -  More than 1 previous chemotherapy
Clinical trial NCT00320359 (phase 3, status: completed)
Conditions: lung cancer, small cell
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: intravenous topotecan/cisplatin, intravenous etoposide/cisplatin
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  Evaluable extensive small cell lung cancer, extensive disease.

          -  Eastern Cooperative Oncology Group (ECOG) performance status < 2.

          -  Life expectancy > 3 months.

          -  Fit to receive any of the treatments.

          -  No prior chemotherapy.

          -  Written informed consent.

        Exclusion Criteria:

          -  Extensive disease treatable with radiotherapy.

          -  Past or current history of other malignant disease.

          -  Prior chemotherapy.

          -  Pregnancy, lactating or lack of effective contraception.

          -  Concurrent severe medical problems other than small cell lung cancer.

          -  Patients with central nervous system metastases receiving more than 12 mg /day
             dexamethasone or equivalent to control symptoms.
Clinical trial NCT00003389 (phase 3, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: doxorubicin, bleomycin, vinblastine, dacarbazine, vincristine, mechlorethamine, etoposide, prednisone, cyclophosphamide
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)C1=C(C)C(N)=NC(=N1)[C@H](CC(N)=O)NC[C@H](N)C(N)=O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)C1=CN=CN1)C(=O)NCCC1=NC(=CS1)C1=NC(=CS1)C(=O)NCCC[S+](C)C, N[C@@H](CCCNC(N)=N)C(O)=O, N1C=CN=C1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, CN(CCCl)CCCl, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion criteria:

          -  Histologically proven previously untreated classical Hodgkin's lymphoma

          -  The following stages are eligible:

               -  Locally extensive: Stage I-IIA/B with massive mediastinal adenopathy

               -  Advanced: Stage III or IV

          -  Measurable or evaluable disease

          -  Age of 16 and over

          -  ECOG Performance status 0-2

          -  Disease-free of prior invasive malignancies for >5 years with the exception of
             curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in
             situ of the cervix

          -  White blood cell (WBC) at least 4,000/mm³, (unless documented bone marrow involvement)

          -  Platelet count at least 100,000/mm³ (unless documented bone marrow involvement)

          -  Bilirubin no greater than 5.0 mg/dL

          -  Creatinine no greater than 2.0 mg/dL

          -  Ejection fraction determination recommended if over age 50 and/or have a history of
             cardiac disease

          -  Fertile patients must use effective contraception

          -  Prior corticosteroids allowed

          -  Prior surgery allowed

        Exclusion criteria:

          -  Pregnant or nursing

          -  Prior radiotherapy

          -  Prior chemotherapy

          -  Human immunodeficiency virus (HIV) positive